Abstract: Described herein are therapeutic compositions comprising heparin-associated polypeptides useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries.
Type:
Application
Filed:
December 22, 2020
Publication date:
June 13, 2024
Applicant:
Juvena Therapeutics, Inc.
Inventors:
Hanadie Yousef, Jeremy O'Connell, Thach Mai, Rami Jaafar
Abstract: Described herein are therapeutic compositions comprising heparin-associated polypeptides useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries.
Type:
Application
Filed:
February 1, 2023
Publication date:
December 21, 2023
Applicant:
Juvena Therapeutics, Inc.
Inventors:
Hanadie Yousef, Jeremy O'Connell, Thach Mai, Rami Jaafar
Abstract: Described herein are polypeptides comprising an FGF17, IGF2, or BMP? amino acid sequence and an amino acid sequence from a heterologous polypeptide useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries. Also described herein are synergistic combinations of a Fibroblast Growth Factor Receptor agonist and a glycosaminoglycan, an Insulin-like Growth Factor 1 Receptor (IGF1R) agonist and a short chain fatty acid, and BMP receptor agonists and mTOR activators and/or glycosaminoglycans. Also described are methods of treating muscle and soft-tissue diseases comprising administering the polypeptides and/or synergistic compositions.
Type:
Application
Filed:
December 22, 2020
Publication date:
December 14, 2023
Applicant:
Juvena Therapeutics, Inc.
Inventors:
Hanadie Yousef, Jeremy O'Connell, Thach Mai, Rami Jaafar, Zhihua Li
Abstract: Described herein are polypeptides comprising an FGF17, IGF2, or BMP7 amino acid sequence and an amino acid sequence from a heterologous polypeptide useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries. Also described herein are synergistic combinations of a Fibroblast Growth Factor Receptor agonist and a glycosaminoglycan, an Insulin-like Growth Factor 1 Receptor (IGF1R) agonist and a short chain fatty acid, and BMP receptor agonists and mTOR activators and/or glycosaminoglycans. Also described are methods of treating muscle and soft-tissue diseases comprising administering the polypeptides and/or synergistic compositions.
Type:
Application
Filed:
February 1, 2023
Publication date:
October 5, 2023
Applicant:
Juvena Therapeutics, Inc.
Inventors:
Hanadie Yousef, Jeremy O'Connell, Thach Mai, Rami Jaafar, Zhihua Li
Abstract: Described herein are polypeptides comprising an IGF2 amino acid sequence and an amino acid sequence from a heterologous polypeptide useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries. Mutations within the IGF2 amino acid sequence improved the stability of the molecule by reducing backbone cleavage. Also described herein are synergistic combinations of an Insulin-like Growth Factor 1 Receptor (IGF1R) agonist and a short chain fatty acid. Also described are methods of treating muscle and soft-tissue diseases comprising administering the polypeptides and/or synergistic compositions.
Type:
Application
Filed:
June 10, 2022
Publication date:
December 29, 2022
Applicant:
Juvena Therapeutics, Inc.
Inventors:
Hanadie Yousef, Jeremy O'Connell, Thach Mai, Zhihua Li
Abstract: Described herein are therapeutic compositions comprising heparin-associated polypeptides useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries.
Type:
Application
Filed:
October 16, 2020
Publication date:
February 11, 2021
Applicant:
Juvena Therapeutics, Inc.
Inventors:
Hanadie Yousef, Jeremy O'Connell, Thach Mai
Abstract: Described herein are therapeutic compositions comprising heparin-associated polypeptides useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries.
Type:
Grant
Filed:
June 27, 2019
Date of Patent:
November 3, 2020
Assignee:
Juvena Therapeutics, Inc.
Inventors:
Hanadie Yousef, Thach Mai, Jeremy O'Connell